BOTALYS

Their core work

BOTALYS is a Belgian plant biotechnology SME specializing in the controlled cultivation of high-value plant roots for use in nutraceuticals, pharmaceuticals, and cosmetics. Their core technology centers on proprietary bioreactor and hydroponic systems that accelerate the growth of medicinal plant roots — plant parts that are typically slow-growing and difficult to harvest at scale. By cultivating roots in a controlled environment rather than extracting them from wild or field-grown plants, they enable consistent, scalable, and potentially more sustainable production of botanical active ingredients. Their work sits at the intersection of agri-tech, plant biology, and specialty ingredient supply chains.

What they specialise in

How they've shifted over time

BOTALYS entered the H2020 programme in 2017 with a feasibility study (SME Phase 1) exploring a bioreactor concept for accelerating plant root growth. By 2019, they had moved to full commercial development under Phase 2, with the technology description shifting from "bioreactor" to "hydroponic technology" — suggesting they refined or pivoted their cultivation approach based on Phase 1 findings. The trajectory is one of a single focused technology being progressively de-risked and scaled up rather than a diversifying research portfolio.

BOTALYS is on a clear commercialization track — having completed SME Phase 2 by 2021, they are likely past the EU-funded R&D stage and focused on market entry, meaning future collaborations would more likely be commercial partnerships than research projects.

How they like to work

BOTALYS operates exclusively as a project coordinator and appears to have driven both Rhizomia projects independently, with no registered consortium partners in the H2020 data. This suggests a self-sufficient, internally-driven innovation model typical of deep-tech SMEs building proprietary technology rather than collaborative research platforms. A potential partner should expect to engage with them as a customer, supplier, or licensing partner rather than as a co-developer in a large EU consortium.

BOTALYS has no recorded consortium partners in the H2020 database, suggesting their EU-funded work was conducted as a solo SME project rather than through collaborative networks. Their geographic footprint through EU funding is limited to Belgium.

What sets them apart

BOTALYS occupies a specific niche that few companies address: the industrial-scale production of plant roots — a botanical raw material category that is notoriously difficult to source consistently from conventional agriculture or wild harvesting. Their technology removes the bottleneck between promising medicinal plants and manufacturable ingredient volumes, which is a genuine supply-chain problem for nutraceutical and pharmaceutical formulators. For any company that relies on root-derived botanical extracts and struggles with supply consistency or quality variation, BOTALYS offers a direct technological solution backed by EU-validated R&D.

Highlights from their portfolio

• Rhizomia (Phase 2)
  At €2.2M, this SME Instrument Phase 2 grant represents a full commercial development award — one of the most competitive EU funding instruments for SMEs — confirming external validation of BOTALYS's technology and market case.
• Rhizomia (Phase 1)
  The successful Phase 1 feasibility study (2017) is notable because it directly unlocked the much larger Phase 2 investment, showing a clean technology validation and scale-up pathway within a two-year window.